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Abstract 
The solubilities of five sparingly soluble drug-compounds in water were mea-
sured at constant temperatures (298.2 and 310.2 K) by the classical saturation 
shake-flask method. All substances presented in this work are derivatives of 
anthranilic acid: flufenamic acid (FLU), mefenamic acid (MEF) niflumic acid 
(NIF), diclofenac sodium (DIC) and meclofenamic sodium (MEC). All of them 
have anti-inflammatory action. Since the aqueous solubility of the ionized drug 
is significantly higher than the unionized, the experimental conditions that 
affect equilibrium solubility values such as composition of aqueous buffer were 
examined. The Henderson-Hasselbalch (HH) relationship was used to predict 
the pH-dependent solubility profiles of chosen drugs at two temperatures. For 
this purpose the pKa values of the investigated drugs were determined using 
the Bates-Schwarzenbach spectrophotometric method at a temperature of 
310.2 K. At temperature of 298.2 K these values were reported previously. 
Similar values of pKa were obtained from the solubility measurements. 
Keywords: derivatives of anthranilic acid, pH-solubility profile, pKa; 
shake flask method, Henderson-Hasselbalch approach. 
 
 
The solubility of a drug is defined as the maxi-
mum quantity of a drug dissolved in a given volume of 
a solvent at chosen temperature, pressure and pH. 
For ionizable drugs, the solubility can be affected by 
the pH of the solution, and the intrinsic solubility (S0) 
is defined as the concentration of a saturated solution 
of the neutral form of the drug, in equilibrium with its 
solid at constant temperature and pressure. 
Nowadays, drug design approaches based on a 
combination of chemistry and quantitative structure- 
–activity relationship led to new active substances that 
are less water soluble and more lipophilic. Not very 
lipophilic drugs reveal lower solubility in water and 
have trouble crossing membranes. The acidic group 
of a drug molecule becomes negatively charged by 
losing a hydrogen ion at pH < 7. Research in phar-
maceutical chemistry has devoted little attention to 
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the physicochemical properties of the chemical leads 
and has focused mainly on optimization of the in vitro 
activity [1–3]. The rate at which a drug goes into the 
solution when it is dissolved in an acidic or a basic 
medium is proportional to the solubility of the drug. 
Many drugs have different solubilities at different pHs. 
These pH-dependent solubility differences lead to pH- 
-dependent dissolution profiles. The solubility-pH pro-
file of drugs or amines has already been reported by 
many authors [4–13]. 
The Henderson-Hasselbalch (HH) equation [14] 
has been used many times for the mathematical des-
cription of the solubility-pH profile of drugs or amines 
existing in the solution as a monomer [4,6,7]. 
Aqueous solubility has an essential role in the 
bioavailability of oral drug formulations. There is an 
established classification, namely, the biopharma-
ceutical classification system (BCS), which divides 
drugs into four classes in terms of their solubility and 
permeability [15]. The BCS classification correlates 
the in vitro solubility and permeability to the in vivo 
bioavailability. 
In recent years, the problem of drug solubility in 
water has become more acute and more common as 
pharmaceutical companies have improved drugs for 
certain therapeutic areas [16]. The accuracy of many A. POBUDKOWSKA, U. DOMAŃSKA: STUDY OF PH-DEPENDENT DRUGS…  Chem. Ind. Chem. Eng. Q. 20 (1) 115−126 (2014) 
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predictive methods can be discussed when it is pos-
sible to compare calculated and measured solubility 
[17,18]. A number of useful experimental methods are 
reviewed, including the miniaturized shake-flask mic-
rotitre plate, the micro-solubility self-calibrating direct 
UV, the potentiometric and micro-dissolution methods 
[5] as well as the “new shake-flask method” [19].  
The aim of the present study was to measure 
the solubility of five ionisable drugs: flufenamic acid 
(FLU), mefenamic acid (MEF), niflumic acid (NIF), 
diclofenac sodium (DIC) and meclofenamic sodium 
(MEC) at two temperatures, 298.2 and 310.2 K using 
the traditional shake-flask solubility method. We have 
already measured the thermodynamic solubility of 
these drugs as a function of temperature at natural pH 
7 in water, ethanol and 1-octanol [20–22]. These 
results will be compared to the buffer solutions at the 
same temperature and pH. The solubility-pH profile of 
mefenamic acid as well as the pKa values at two tem-
peratures, 298.2 and 310.2 K have also been pre-
sented earlier [5] and will be compared to our new 
values. 
The novelty of the present work is to show the 
effect of pH on the solubility in buffer solutions at two 
temperatures and ambient pressure. The intrinsic 
solubility,  S0 at two temperatures will be developed 
from the solubility-pH profile measurements. The pKa 
values obtained using the Bates-Schwarzenbach 
spectrophotometric method will be compared with the 
pKa values, coming from the solubility-pH profile mea-
surements. The sigmoidal relationship of solubilities 
of weak acid drugs and two salts will be predicted 
using the HH equation. 
MATERIALS AND METHODS 
Chemicals and reagents 
The following investigated drugs were obtained 
from Sigma Aldrich: flufenamic acid (CAS registry No. 
530-78-9, ≥0.99), mefenamic acid (CAS registry No. 
61-68-7, ≥0.99), niflumic acid (CAS registry No. 4394-
00-7; ≥0.99), diclofenac sodium salt (CAS registry No. 
15307-79-6;  ≥0.99), meclofenamic sodium (CAS 
registry No. 6385-02-0; ≥0.99). The drugs were used 
without purification and were used as powder or small 
crystals. Other chemicals were as follows: methanol 
for HPLC – super gradient (CAS registry No. 67-56-1, 
POCH, 99.9%), hydrochloric acid (CAS registry No. 
7647-01-0, POCH), sodium hydroxide (CAS registry 
No. 1310-73-2, POCH), dipotassium hydrogen 
phosphate (CAS registry No. 7758-11-4, POCH, 
≥0.99), disodium tetraborate (CAS registry No. 1303-
96-4, POCH, ≥0.999), sodium chloride (CAS registry 
No. 231-598-3, POCH, ≥0.999), 
All solvents were filtrated twice with the Schott 
funnel with 4 μm pores. They were stored under 
freshly activated molecular sieves of type 4 Å. Water 
used as a solvent was twice distilled, degassed and 
filtered with Milipore Elix 3. The names, abbreviations, 
systematic (IUPAC) names, molecular formulas and 
molar mass of the drugs are given in Table 1. 
The pKa measurements 
The pKa measurements were performed with the 
Bates-Schwarzenbach (BS) method using a UV-Vis 
spectrophotometer (Perkin Elmer Life and Analytical 
Sciences, Shelton, USA). The method was described 
in our previous paper [21]. The UV-Vis spectra for 
acidity constant measurements at temperature 310.2 
K are presented at three conditions: buffer, 0.2 M HCl, 
and 0.12 M NaOH in Figures 1–5. The pKa values are 
also determined from the solubility-pH profiles and 
are compared to those obtained with BS method. 
pH-Dependent solubility studies 
The solubility experiment was performed with a 
new small-scale shake flask method [23] at constant 
temperatures of 298.2 and 310.2 K. The shake-flask 
method proposed by Higuchi and Connors [24] is the 
most reliable and widely used solubility measurement 
method. This method determines thermodynamic 
solubility and could be carried out in several steps. 
Each drug was added in excess to 10 ml of dipo-
tassium hydrogen phosphate (0.15 M) in a test tube. 
The test tubes were placed on a plate shaker. Using a 
pH-meter up to a stable pH (solubility equilibrium), the 
pH of each drug suspension was measured and 
adjusted if necessary with either diluted 0.2 M HCl, or 
Table 1. Basic properties of drugs used in the investigations 
Name of compound/ 
abbreviation 
Systematic (IUPAC) name  Molecular formula 
Molar mass 
M / g mol
–1 
Flufenamic acid/ FLU  2-{[3-(Trifluoromethyl)phenyl]amino}benzoic acid  C14H10F3NO2 281.23 
Mefenamic acid/MEF  2-(2,3-Dimethylphenyl)aminobenzoic acid  C15H15NO2  241.30 
Niflumic acid/ NIF  2-{[3-(Trifluoromethyl)phenyl]amino}nicotinic acid  C13H9F3N2O2  282.22 
Diclofenac sodium/ DIC  2-(2-(2,6-Dichlorophenylamino)phenyl)acetic sodium  C14H10Cl2NO2Na 318.13 
Meclofenamic sodium/MEC  2-[(2,6-Dichloro-3-methylphenyl)amino]benzoic acid, sodium salt  C14H10Cl2NO2Na 318.13 A. POBUDKOWSKA, U. DOMAŃSKA: STUDY OF PH-DEPENDENT DRUGS…  Chem. Ind. Chem. Eng. Q. 20 (1) 115−126 (2014) 
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Figure 1. UV-Vis spectra for acidity constant measurement at temperature 310.2 K for flufenamic acid + solvent: () buffer, () 0.2 M 
HCl, () 0.2 M NaOH. 
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Figure 2. UV-Vis spectra for acidity constant measurement at temperature 310.2 K for mefenamic acid + solvent: () buffer, () 0.2 M 
HCl, () 0.2 M NaOH. 
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Figure 3. UV-Vis spectra for acidity constant measurement at temperature 310.2 K for niflumic acid + solvent: () buffer, () 0.2 M HCl, 
() 0.2 M NaOH. 
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Figure 4. UV-Vis spectra for acidity constant measurement at temperature 310.2 K for diclofenac sodium salt + solvent: () buffer, 
() 0.2 M HCl, () 0.2 M NaOH. A. POBUDKOWSKA, U. DOMAŃSKA: STUDY OF PH-DEPENDENT DRUGS…  Chem. Ind. Chem. Eng. Q. 20 (1) 115−126 (2014) 
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Figure 5. UV-Vis spectra for acidity constant measurement at temperature 310.2 K for meclofenamic sodium salt + solvent: () buffer, 
() 0.2 M HCl, () 0.2 M NaOH. 
0.2 M NaOH to a selected pH value. The experiment 
was completed when at least three pH measurements 
performed at an early, an intermediate and a late 
time-point of the 24 h period resulted in the same pH 
value. The equilibrium solubility was attained within 
24 h. The pH values were also measured for the 
supernatants obtained after centrifugation, in order to 
certify that the drug solutions analyzed had the same 
pH value as the suspensions. Measurements were 
made using pH-meter (CPC-401 Elmetron) with an 
associated uncertainty of 0.01. The test-tubes were 
thermostated by a temperature control thermostat 
(Lauda A3, Germany) through the jacket of the vessel 
with uncertainty 0.1 K. Samples were withdrawn after 
24 h, since a previous study had shown that a majo-
rity of drugs reach their solubility equilibrium within 
this time-scale [7,23]. Furthermore, this time-scale 
often is used in drug development settings. Excess 
solid was equilibrated using a rotating-bottle appa-
ratus (Hettich Zenrifugen, EBA 20) at 300000 rpm for 
30 min. Following centrifugation, the supernatant was 
collected and used for solubility and pH determi-
nations. The concentration of the drug in the super-
natant solution was determined by an HPLC proce-
dure with single-wavelength UV detection. All com-
pounds were analyzed in quadruplicates at each 
investigated pH value, as it was shown in the pre-
vious works [23,25,26]. 
The prerequisites in the selection of the buffer 
system were that the buffer should display an osmotic 
pressure comparable to the osmotic pressure of the 
intestinal fluid (278 mOsm/kg) and that it should have 
an acceptable buffer capacity. Thus, 150 mM K2HPO4 
(340 mOsm/kg) was chosen as buffer, and this buffer 
was mixed with pure drug to obtain the desired pH 
values. For pH below the pKa value the HCl was 
added and for the values above the pKa values, the 
NaOH was added [7]. 
HPLC Analysis 
Each sample contained excess of drug and buf-
fer solutions, sodium hydroxide or hydrochloric acid 
solution. Drug concentration in each sample was 
measured using an HPLC-UV-Vis apparatus delivered 
by Agilent Technologies, consisting of: 1200 Series 
Quat pump, 1200 vacuum degasser, 1200 DAD/ 
/MWD. A C18 analytical column (4.6 mm×150 mm) 
with a mean particle size of 5 μm was used. One buf-
fer was prepared for mobile phase: disodium tetrabo-
rate (0.01038 M Na2B4O7 and 0.01925 M NaCl). As a 
mobile phase two solutions were used: methanol (A) 
and borate buffer, pH 9 (B). Injection volumes of 5 μl 
were used during the analysis. The chromatographic 
conditions for all the drugs are shown in Table 2. 
Data analysis 
The modified HH equation may be used for the 
pH-dependent solubility prediction in two forms, for 
monoprotic acids: 
Table 2. Condition during chromatography separation 
Compound 
Mobile phase 
Flow rate, ml min
–1  λ / nm 
Methanol (A), %  Borate buffer (B), % 
FLU 75  25  1.5  290 
MEF 75  25  1.5  210 
NIF 65  35  1.5  290 
DIC 80  20  1.0  280 
MEC 70  30  1.0  210 A. POBUDKOWSKA, U. DOMAŃSKA: STUDY OF PH-DEPENDENT DRUGS…  Chem. Ind. Chem. Eng. Q. 20 (1) 115−126 (2014) 
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pH p a
0 log log log(1 10 )
K SS
− =+ +  (1a) 
and for monoprotic bases: 
pap H
0 log log log(1 10 )
K SS
− =+ +  (1b) 
where S0 is the intrinsic solubility, S is the predicted 
solubility at a given pH, and pKa is a pH at which the 
concentration of unionized and ionized forms of a 
monoprotic drug in the solution are equal. The HH 
equation describes solubility as a function of pH. This 
equation always predicts an increasing solubility of all 
weak acids as pH increases, and descending solu-
bility of bases when pH increases. In this paper all 
solubility values, S (mol dm
–3) are expressed as log S 
and are calculated from the HH equation for mono-
protic acids (Eq. (1a)). The intrinsic solubility, S0, was 
developed from the solubility-pH profile. Using the HH 
equation, the calculated curves were drawn for all 
experimentally studied drugs. 
RESULTS AND DISCUSSION  
The pKa of an ionisable compound is an impor-
tant property, describing the charge state of the drug 
at a certain pH. However, according to Avdeef [6], it is 
not recommended to determine pKa values from the 
solubility-pH measurements (pKa
S). The results listed 
in Table 3 show a reasonably good agreement 
between the results obtained by the two different 
methods at two temperatures: from the solubility-pH 
measurements (pKa
S), and with the precise spectro-
photometric Bates-Schwarzenbach method (pKa
B-S). 
The pKa
S values were obtained from the crossing of 
two lines interpolated from the experimental points for 
the unionized and ionized form of the chosen drug. 
The parameters and correlation coefficients are listed 
in Table 3. All the literature data of pKa values, 
obtained with different methods (including ours at 
298.2 K for comparison) are presented in Table 4. 
Generally, our values are higher than those from lite-
rature with the exception of MEF. In our opinion the 
Bates-Schwarzenbach method is more precise 
because it does not use the co-solvent and the extra-
polated values to pure aqueous solutions. 
The classical shake-flask method was applied to 
measure the equilibrium solubility at two temperatures 
for five drugs over a wide pH range from 2 to 8 or 9. 
The time of stirring was chosen as 24 h at the same 
temperature and pH to get the repeatable results. 
After stirring, the two phases (solution and solid mate-
rial) of the saturated solution were separated, and 
after 6 h (the necessary time needed for the sepa-
ration of two phases) the supernatant was taken out 
for the concentration of drug measurements by 
HPLC-UV-Vis spectrometry. The theoretical HH solu-
bility,  S, was predicted based on the pKa
B-S values 
and the intrinsic solubilities, S0 determined by the 
shake-flask method at two temperatures. Data are 
listed in Table 4 together with the literature data of S0. 
The results are discussed for each drug separately. 
Flufenamic acid 
During the last few years there were different 
values of pKa  and  S0 discussed in the literature at 
temperature 298.2 K for FLU. Our value of pKa = 4.62 
[20] is close to the presented by Muñoz et al. [27], 
pKa = 4.17 and higher than all remaining data. In our 
opinion, the reason may also be insufficient control of 
the equilibrium temperature. The same parameters 
are responsible also for the values of the intrinsic 
solubility, S0. The value obtained in this work at T = 
Table 3. The linear regression parameters, a1, b1 for the unionized form and a2, b2 for the ionized form, the corresponding correlation 
coefficients, R1 and R2, the pKa
S developed from the solubility-pH profile and the pKa
B-S obtained from the Bates-Schwarzenbach method
Compound 
Parameter 
pKa
S  pKa
B-S 
a1  b1  R1
2  a2  b2  R2
2 
298.1 K 
FLU  0.159 -5.835 0.989 1.124  -10.290  0.987  4.62  4.62  [20] 
MEF  0.134 -6.698 0.939 1.455  -11.818  0.998  3.87  3.88  [21]
 
NIF  0.100 -4.465 0.959 0.677 -7.035 0.991  4.45  4.42  [20]
 
DIC  0.061 -4.322 0.968 1.022 -9.767 0.997  5.66  5.70  [20]
 
MEC  0.079 -7.138 0.901 1.073 11.543 0.994  4.43  4.39  [22]
 
310.2 K 
FLU  0.150 -4.996 0.874 1.143  -10.220  0.997  5.26  5.23 
MEF  0.184 -6.159 0.976 1.690  -12.680  0.998  4.33  4.33 
NIF  0.142 -4.466 0.939 0.743 -7.234 0.998  4.60  4.60 
DIC  0.096 -4.387 0.972 0.768 -7.423 0.998  4.52  4.51 
MEC  -0.010 -6.631  0.912  1.036 -10.810 0.999  4.00  3.99 A. POBUDKOWSKA, U. DOMAŃSKA: STUDY OF PH-DEPENDENT DRUGS…  Chem. Ind. Chem. Eng. Q. 20 (1) 115−126 (2014) 
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= 298.2 K, S0 = 7.40×10
–6 mol dm
–3 is close to that 
presented by Avdeef [5], S0 = 8.32×10
–6 mol dm
–3, or 
by Box et al. [28], S0 = 4.47×10
–6 mol dm
–3. The two 
other values presented in Table 4 are higher. New 
values, presented in this work at T  = 310.2 K are: 
pKa = 5.23 and S0 = 5.20×10
–5 mol dm
–3. As for most 
of chemical compounds, with an increase of tempe-
rature the solubility increases. The pKa also increases 
with an increase of temperature. Figure 6 shows the 
pH-equilibrium solubility profile for FLU at 298.2 
(Figure 6a) and 310.2 K (Figure 6b). As the pKa 
values inform below pH 4.6 at 298.1 K and pH 5.2 at 
310.2 K, a constant value of the solubility of this 
unionized form of weak acid is observed. Above these 
values of pH the compound transformed to the 
anionic form. At around pH 8 the horizontal plateau 
due to sodium-salt solubility was observed. The theo-
retical HH calculated curve from Eq. (1a) closely 
follows the experimental points. 
Mefenamic acid 
The mefenamic acid is the only compound for 
which the solubility-pH profile at two temperatures 
(298.2 and 310.2 K) was presented in the open lite-
rature [6]. The pKa = 4.33 value at 310.2 K is close to 
the published earlier pKa = 4.64 [6]. The other lite-
rature values of pKa and intrinsic solubility are close 
to ours [28,29] or much higher i.e., S0 = 1.7×10
–4 mol 
dm
–3 [30] in comparison with our value S0 = 5.75×10
–7 
mol dm
–3 at T = 298.2 K. Also the S0 = 3.31×10
–4 mol 
dm
–3 at T = 310.2 K [31] is far from our data S0 = 
= 3.55×10
–6 mol dm
–3. All data are presented in Table 
4. The solubility-pH profile for MEF is shown in 
Figures 7a and 7b for 298.2 and 310.2 K, res-
pectively. Below pH 3.8 and 4.3 at 298.2 and 310.2 K 
there is a constant value of S of the unionized acid 
form. Above these two pH values MEF is present in 
the solution as ionized form. At around pH 6.5 the 
horizontal plateau due to sodium-salt solubility was 
observed. A significant deviation from the HH eq. can 
be observed for the ionized form of MEF (see Figure 
7a and 7b). The slope of the linear part of the pH- 
–solubility curve is far from the theoretical HH eq. 
defined as –1 for monoprotic weak acids. This can be 
explained as the salting out effect of phosphate 
counter-ions [4,7]. The pKa and solubility increase 
with an increase of temperature. 
Niflumic acid 
NIF is a popular drug for which the different 
values of pKa and S0 are presented in the literature at 
temperature 298.2 K. Our value of pKa = 4.42 [20] is 
close to the presented by Box et al. [28, 32] pKa = 
= 4.44 and higher than presented by Takács-Novák et 
al. [33], pKa = 2.28. The reason may be the different 
experimental method and the buffer used. The value 
of the intrinsic solubility at temperature 298.2 K, S0 = 
= 7.61×10
–5 mol dm
–3 is close to those presented by 
Table 4. The literature values of pKa
lit, intrinsic solubility, S0
lit, and experimental intrinsic solubility, S0
exp, developed from solubility-pH 
profile at two temperatures, 298.2 and 310.2 K 
Compound pKa
lit  S0
lit/ mol dm
–3  S0
exp/ mol dm
–3 
FLU 4.62
B-S,a 
3.97
b,c 
4.17
d 
3.84
e 
3.90
f 
4.47×10
-6 b 
8.32×10
-6 g 
3.24×10
-5 h 
2.38×10
-5 i 
7.40×10
-6 
5.20×10
-5 (310.2 K) 
MEF 3.88
B-S,j 
4.22
b,c 
4.5
 g 
4.64 (310.2 K)
g 
4.57×10
-7b,c 
8.70×10
-8 g,k 
1.70×10
-4 i; 1.66×10
-6 l 
3.31×10
-4 (310.2 K)
l; 2.45×10
-7 (310.2 K)
g 
5.75×10
-7 
3.55×10
-6 (310.2 K) 
(310.2 K) 
NIF 4.42
B-S,a 
4.44
b,m 
4.86
n 
2.28
n 
3.39×10
-5b,m 
1.05×10
-4 m 
7.61×10
-5 
1.35×10
-4 (310.2 K) 
DIC 5.70
B-S,a 
3.99
o,p 
4.00
o 
3.90
r 
2.58×10
-6 o, p  1.01×10
-4 
1.16×10
-4 (310.2 K)
 
MEC 4.39
B-S,s 
4.10
b 
1.38×10
-7b  1.58×10
-7 
2.11×10
-7 (310.2 K) 
aRef. [20]; 
bRef. [28]; 
cRef. [29]; 
dRef. [27]; 
eRef. [35]; 
fRef. [36]; 
gRef. [6]; 
 hRef. [37]; 
iRef. [30]; 
jRef. [21]; 
kRef. [5]; 
lRef. [31]; 
mRef. [32]; 
nRef. [33]; 
oRef. [34];
pRef. [9]; 
rRef. [38]; 
sRef. [22] A. POBUDKOWSKA, U. DOMAŃSKA: STUDY OF PH-DEPENDENT DRUGS…  Chem. Ind. Chem. Eng. Q. 20 (1) 115−126 (2014) 
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Figure 6. pH-dependent solubility profile of flufenamic acid (points are log S values measured by shake-flask method): a) experimental 
data at 298.2 K; b) experimental data at 310.2 K; the solid line was calculated with the Henderson-Hasselbalch equation; the dashed line 
was linear interpolation of the experimental points. 
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Figure 7. pH-dependent solubility profile of mefenamic acid (points are log S values measured by shake-flask method): a) experimental 
data at 298.2 K; b) experimental data at 310.2 K; the solid line was calculated with the Henderson-Hasselbalch equation; the dashed line 
was linear interpolation of the experimental points. 
Box  et al. [28,32] (see Table 4). The new values, 
presented in this work at T = 310.2 K are: pKa = 4.60 
and S0 = 1.35×10
–4 mol dm
–3. The pKa and S increase 
when the temperature increases. Figure 8 shows the 
pH-equilibrium solubility profile for NIF at 298.2 
(Figure 8a) and 310.2 K (Figure 8b). Below pH 4.4 at 
298.2 K and pH 4.6 at 310.2 K a constant value of the 
solubility of the unionized form of NIF is observed. 
Above these values of pH the compound transformed 
to the anionic form. At around pH 7.5, the horizontal 
plateau due to sodium-salt solubility was observed. 
The theoretical HH calculated curve (Eq. (1a)) closely A. POBUDKOWSKA, U. DOMAŃSKA: STUDY OF PH-DEPENDENT DRUGS…  Chem. Ind. Chem. Eng. Q. 20 (1) 115−126 (2014) 
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Figure 8. pH-dependent solubility profile of niflumic acid (points are log S values measured by shake-flask method): a) experimental data 
at 298.2 K; b) experimental data at 310.2 K. The solid line is calculated with the Henderson-Hasselbalch equation; the dashed line is a 
linear interpolation of the experimental points. 
follows the experimental points for the unionized form 
and slightly deviates for ionized form. The pKa and 
solubility increase with an increase of temperature. 
Diclofenac sodium 
The sodium salt of diclofenac, DIC was used for 
the solubility measurements. The pKa values are 5.70 
[20] at T = 298.2 K and 4.51 at T = 310.2 K. All lite-
rature values at 298.2 K are much lower, which is 
shown in Table 4. Its intrinsic solubility is S0 = 
= 1.01×10
–4 mol dm
–3 at T = 298.2 K, which is much 
higher than that in literature S0 = 2.58×10
–6 mol dm
–3 
[9,34]. The intrinsic solubility obtained by the shake-
flak method in this work at T = 310.2 K is S0 = 
= 1.16×10
–4 mol dm
–3. Solubility increases as the tem-
perature increases but the pKa decreases. In the later 
the inverse property is observed in comparison with 
weak acids. Figure 9 show the log S-pH profile of 
DIC. In solution at low pH DIC as an acid predo-
minates; at high pH the ionized form of salt and asso-
ciates of sodium cation predominate. The HH equa-
tion excellent describes the solubility, especially at 
T = 298.2 K. 
Meclofenamic sodium 
The meclofenamic sodium salt, MEC was used 
for the solubility-pH profile measurements. The pKa 
values are 4.39 [22] and 3.99 at T = 298.2 K and T =  
= 310.2 K respectively. The literature value at T = 
= 298.2 K is close to that, pKa = 4.10 [28] (see Table 
4). The intrinsic solubility is S0 = 1.58×10
–7 mol dm
–3 at 
T = 298.2 K, which is similar to that in literature S0 = 
= 1.38×10
–7 mol dm
–3 [28]. The intrinsic solubility 
obtained by the shake-flak method in this work at T =  
= 310.2 K is S0 = 2.11×10
-7 mol dm
–3. Solubility 
increases as the temperature increases but the pKa 
decreases as it was observed for DIC. Figure 10 
shows the log S-pH profile of MEC. Below the pKa 
values a constant value of the solubility of the 
unionized form of MEC is observed. In solution at low 
pH MEC as an acid predominates; at high pH the 
ionized form of salt and associates of sodium cation 
predominate. The HH equation fits extremely well to 
measured solubility values at both temperatures. A. POBUDKOWSKA, U. DOMAŃSKA: STUDY OF PH-DEPENDENT DRUGS…  Chem. Ind. Chem. Eng. Q. 20 (1) 115−126 (2014) 
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Figure 9. pH-dependent solubility profile of diclofenac sodium (points are log S values measured by shake-flask method): a) ♦, 
experimental data at 298.2 K; b) , experimental data at 310.2 K. The solid line is calculated with the Henderson-Hasselbalch equation; 
the dashed line is a linear interpolation of the experimental points at 298.2 K. 
Some practical comparisons 
The values of pKa increase as the temperature 
rises for weak acids and decrease for sodium salts. 
The dissociation reaction and the corresponding con-
stants for a monoprotic weak acids and other sub-
stances were defined in an excellent review paper [6]. 
The dissociation, dimerization, or aggregation cons-
tant of different species in the solution is a tempera-
ture dependent constant. The van’t Hoff equation 
shows that for a reaction that is exothermic under 
standard conditions (ΔrH < 0) the equilibrium constant 
K decreases as the temperature rises, which is 
observed for the measured sodium salts. The oppo-
site occurs in the case of endothermic reactions, as 
for acids measured in this work. 
The shake-flask method, used by pharmaceut-
ical laboratories for the measurement of solubility of 
drugs in an aqueous buffer solution, assumes the 
thermodynamic equilibrium between the solid and 
liquid phase at constant temperature and pressure in 
saturated solution [4]. The dynamic solubility mea-
surements at natural pH, or shake–flask method at 
natural pH used in physico-chemical, thermodynamic 
models/laboratories also assumes the thermodyna-
mic equilibrium between the solid and liquid phase at 
constant temperature and pressure in saturated solu-
tion [22]. The only important difference between these 
two methods, as we can see, is an aqueous buffer 
solution in comparison with pure water. The solubility 
of drug in buffer solution reaches equilibrium at cons-
tant pH after few to 24 h. During the first few hours 
the pH of solution changes due to ionization, salt for-
mation, association of cation, or anion of compound, 
the salting out effects coming from the buffer used, 
the common ion effect, the equilibrium formation of 
different associates, self-association by forming 
mixed-charge micelles or micelle-like structures and 
possible aggregation of different species. The influ-
ence of the kind of buffer used was recently discus-
sed for the promethazine pH-equilibrium solubility [4]. 
Table 5 shows the results obtained at the same labo- 
ratory for the same drugs with two different methods 
in pure water solvent, S
T and in an aqueous buffer 
solution at the same temperature, S, an ambient 
pressure and the same pH. In general the solubilities 
of weak acids is higher in an aqueous buffer solutionA. POBUDKOWSKA, U. DOMAŃSKA: STUDY OF PH-DEPENDENT DRUGS…  Chem. Ind. Chem. Eng. Q. 20 (1) 115−126 (2014) 
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Figure 10. pH-dependent solubility profile of meclofenamic sodium (points are log S values measured by shake-flask method): 
a) experimental data at 298.2 K; b) experimental data at 310.2 K. The solid line is calculated with the Henderson-Hasselbalch equation; 
the dashed line is a linear interpolation of the experimental points at 298.2 K. 
Table 5. Solubility of drugs derivatives of anthranilic acid in water obtained by dynamic method in natural pH 7, S
T, and by shake-flask 
method in buffer solutions, S, at pH 7 
Compound  S
T / mol dm
–3  S
  / mol dm
–3 
298.2 K 
FLU 3.38×10
-5a  3.81×10
-3 
MEF <5.55·10
-6b  4.87×10
-3 
NIF 9.11×10
-5a  5.11×10
-3 
DIC 2.89×10
-2a  2.47×10
-3 
MEC 0.903
c  9.31×10
-5 
310.2 K 
FLU 1.49×10
-4a  6.00×10
-3 
MEF <5.55×10
-6b  1.62×10
-2 
NIF 1.39×10
-4a  7.30×10
-3 
DIC 0.202
a  9.19×10
-3 
MEC 2.09
c  2.75×10
-4 
aRef. [20]; 
bRef. [21]; 
cRef. [22] 
but that of the sodium salts are lower. However, MEF 
can exists at pH 7 as a sodium salt, the solubility is 
three ranges of order higher than that coming from 
the dynamic method. It is evident that weak acids 
drugs tend to be more soluble in an aqueous buffer 
solution than would be measured in pure water, or 
predicted by the thermodynamic models. The number 
of polar groups and hydrogen bond donors and 
acceptors always tend to have influence on the solu-
bility [32]. A. POBUDKOWSKA, U. DOMAŃSKA: STUDY OF PH-DEPENDENT DRUGS…  Chem. Ind. Chem. Eng. Q. 20 (1) 115−126 (2014) 
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CONCLUSIONS 
This paper presents a systematic study of the 
pKa (at 310.2 K) and equilibrium solubility-pH profile 
measurements by the saturation shake-flask method 
of five drugs at 298.2 and 310.2 K. The solubility 
results depend on temperature and pH. Each of the 
investigated compounds reveals a specific pH-depen-
dent solubility profile. It was shown that for some 
drugs as mefenamic acid or niflumic acid the HH 
equation has a limited applicability in phosphate buf-
fer. The solubility of all drugs increases with an 
increase of pH and temperature. For all solutions above 
certain pH the characteristic plateau was observed. 
The pKa increases with an increase of temperature 
for weak acids and decreases for sodium salts. 
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NAUČNI RAD 
   ISPITIVANJE RASTVORLJIVOSTI LEKOVA U VODI 
NA RAZLIČITIM pH VREDNOSTIMA 
Rastvorljivost pet slabo rastvornih lekova u vodi je merena pri konstantnim temperaturama 
(298,2 i 310,2 K) klasičnom metodom zasićenja u erlenmajeru. Sve testirane supstance su 
derivati antranilne kiseline: flufenaminska kiselina (FLU), meklofenaminska kiselina (MEF), 
nifluminska kiselina (NIF), diklofenak-natrijum (DIC) i meklofenamik-natrijum (MEC), i 
poseduju anti-inflamatorno dejstvo. Pošto je rastvorljivost u vode jonizovanog leka znatno 
veća nego nejonizovanog, ispitani su eksperimentalni uslovi koji utiču na vrednosti ravno-
težne rastvorljivosti, kao što je sastav vodenog pufera. Henderson-Hasselbalch jednačina 
(HH) je korišćena za predviđanje zavisnosti rastvorljivosti izabranih lekova od pH na 
pomenutim temperaturama. Za ovu svrhu su pKa vrednosti ispitivanih lekova utvrđene 
Bates-Schvarzenbach spektrofotometrijskom metodom na temperaturi 310,2 K, s obzirom 
na to da su vrednosti dobijene pri temperaturi od 298,2 K ranije publikovane. pKa dobijene 
ovim metodama i merenjem rastvorljivosti imaju slične vrednosti. 
Ključne reči: derivati antranilne kiseline, rastvorljivost, pKa, metoda erlenmajera, 
Henderson-Hasselbalchova jednačina. 
 
 